For international buyers, healthcare professionals, and procurement specialists, navigating the quality assurance landscape of generic medicines can be complex. One of the most globally recognized benchmarks for pharmaceutical quality is the WHO Prequalification Programme. This guide explains what WHO prequalification means, how Indian generic medicine manufacturers participate in the program, and why it matters for anyone sourcing affordable, high-quality medicines from India.
🧪 What Is the WHO Prequalification Programme?
The WHO Prequalification Programme (WHO PQ) is a flagship initiative of the World Health Organization that evaluates medicinal products, vaccines, diagnostics, and other health technologies for quality, safety, and efficacy. Established in 2001, the program was originally created to ensure that medicines procured by United Nations agencies — such as UNICEF, UNITAID, and The Global Fund — met acceptable quality standards.
Today, WHO PQ has evolved into the gold standard for pharmaceutical quality assurance in global health procurement. Over 60% of low- and middle-income countries rely on WHO prequalification as a key criterion for medicine registration and procurement.
🔑 How the WHO Prequalification Process Works
The WHO prequalification process involves three main phases:
- Product Dossier Submission — The manufacturer submits a comprehensive dossier following the WHO Common Technical Document (CTD) format, covering quality, safety, and efficacy data.
- Site Inspection — WHO inspectors or delegated regulatory authorities conduct on-site audits of manufacturing facilities to verify Good Manufacturing Practices (GMP) compliance. These inspections are rigorous and unannounced in many cases.
- Ongoing Monitoring — Once prequalified, products undergo continuous surveillance, including batch testing, stability monitoring, and re-inspection every 2–3 years.
The entire process can take 12–24 months from initial submission to prequalification, depending on dossier completeness and inspection outcomes.
🇮🇳 India’s Role in the WHO Prequalification Programme
India is the largest supplier of WHO-prequalified generic medicines globally. Indian pharmaceutical manufacturers account for a significant share of prequalified products across critical therapeutic areas including:
- HIV/AIDS — Antiretroviral drugs (tenofovir, dolutegravir, lamivudine) for adult and pediatric use
- Malaria — Artemisinin-based combination therapies (ACTs) and injectable artesunate
- Tuberculosis — Fixed-dose combinations for drug-sensitive and multidrug-resistant TB
- Hepatitis C — Direct-acting antivirals such as sofosbuvir and daclatasvir
- Diabetes — Metformin, glimepiride, and increasingly, insulin products
- COVID-19 — Remdesivir, favipiravir, and nirmatrelvir/ritonavir (generic Paxlovid) [CITATION NEEDED]
Major Indian pharmaceutical companies with extensive WHO prequalification portfolios include Cipla, Hetero, Viatris (formerly Mylan), Sun Pharma, Lupin, Dr. Reddy’s Laboratories, Aurobindo Pharma, and Zydus Lifesciences [CITATION NEEDED].
✅ How WHO Prequalification Differs from CDSCO Approval
International buyers often ask: “If a medicine is approved by CDSCO (India’s drug regulator), does it also meet WHO standards?”
While CDSCO approval is mandatory for marketing medicines within India, WHO prequalification is a separate, more globally oriented process. Key differences include:
- Scope: CDSCO approval is for the Indian domestic market; WHO PQ is for international procurement by UN agencies and national health programs.
- Inspection Standards: WHO PQ site inspections follow WHO GMP standards, which may include additional requirements beyond Indian Schedule M.
- International Recognition: WHO PQ is accepted by more than 150 countries for registration purposes, whereas CDSCO approval is primarily recognized in India and some neighboring countries.
- Transparency: WHO publishes public assessment reports (WHOPARs) and inspection outcomes, providing full transparency to buyers.
However, a significant development occurred when CDSCO was designated a WHO-Listed Authority (WLA) in 2024 — meaning that medicines approved by CDSCO under a stringent regulatory framework may be eligible for accelerated WHO PQ assessment [CITATION NEEDED]. This recognition streamlines the pathway for Indian generics to achieve WHO prequalification.
🔍 Why WHO Prequalification Matters for International Buyers
For procurement officers, wholesalers, and healthcare institutions looking to source generic medicines from India, WHO prequalification offers several concrete benefits:
- Assured Quality — WHO PQ products have passed rigorous independent review by international experts
- Global Recognition — Prequalified products are accepted in most countries without additional testing
- UN and Donor Procurement — WHO PQ is mandatory for medicines purchased by The Global Fund, UNICEF, and PEPFAR
- Price Benchmarking — WHO publishes reference prices for prequalified products, helping buyers negotiate fair prices
- Reduced Regulatory Burden — Many countries fast-track registration for WHO-prequalified products
📋 How to Verify If an Indian Generic Medicine Is WHO Prequalified
Verifying the WHO prequalification status of an Indian generic medicine is straightforward:
- Visit the WHO Prequalification of Medicines Programme official website:
extranet.who.int/prequal/medicines - Search by medicine name, manufacturer, or therapeutic category
- Check the status (prequalified, under assessment, or withdrawn)
- Review the public assessment report (WHOPAR) for detailed quality and efficacy findings
- Cross-reference the manufacturing site — ensure the site listed in WHO records matches the actual production facility
Buyers can also request the manufacturer to share their WHO Certificate of Prequalification as part of the supplier qualification process.
⚖️ Limitations of WHO Prequalification
While WHO PQ is a powerful quality indicator, it is important to understand its limitations:
- Not all products are prequalified — WHO PQ focuses primarily on priority medicines for global health. Many high-quality Indian generics for chronic conditions (e.g., cardiovascular, neurological) are not submitted for WHO PQ because the market does not require it.
- Manufacturer-driven process — Companies must apply and pay for WHO PQ. Some excellent manufacturers choose not to participate because their target markets (e.g., US, EU, UK) use different regulatory pathways (FDA, EMA, MHRA).
- Product-specific — A manufacturer may have one product prequalified while other products from the same factory are not. Always verify the specific product, not just the company.
🛡️ WHO Prequalification vs. Other Quality Standards
| Standard | Regulator | Best For | Global Acceptance |
|---|---|---|---|
| WHO PQ | World Health Organization | UN procurement, LMIC markets | 150+ countries |
| FDA Approval | US FDA | US market | High, needs country registration |
| EU GMP | European Medicines Agency | EU/EEA market | High, EU mutual recognition |
| CDSCO Approval | India (DCGI) | Indian domestic market | Limited to India and neighbors |
| Schedule M GMP | CDSCO (India) | Indian domestic manufacturing | Basis for WHO PQ eligibility |
Importantly, Indian manufacturers with WHO PQ often also hold FDA and EU GMP approvals, making them some of the most inspected and verified pharmaceutical facilities in the world [CITATION NEEDED].
📌 Key Takeaways for Buyers
- WHO prequalification is a strong but not exclusive indicator of quality — many excellent Indian generics are not WHO PQ but still meet US FDA or EU GMP standards
- Always verify at the product level — a company’s reputation does not guarantee that every product they make is prequalified
- Use WHO PQ as one of multiple verification tools — combine with CDSCO approval, GMP certificates, and independent lab testing for comprehensive quality assurance
- India remains the world’s leading source of WHO-prequalified generic medicines, thanks to its advanced manufacturing infrastructure and regulatory maturity
For a list of verified and reliable pharmaceutical distributors who source WHO-prequalified and CDSCO-approved generic medicines, refer to the IMSDA’s verified member directory.
For more information, contact IMSDA at contact@indiamedicine.org.